Cybin Inc.

NYSE American CYBN

Cybin Inc. EPS (Diluted) for the year ending March 31, 2024: USD -6.95

Cybin Inc. EPS (Diluted) is USD -6.95 for the year ending March 31, 2024, a -4,170.33% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Cybin Inc. EPS (Diluted) for the year ending March 31, 2023 was USD -0.16, a 52.67% change year over year.
Cybin Inc. EPS (Diluted) for the year ending March 31, 2022 was USD -0.34, a -34.94% change year over year.
Cybin Inc. EPS (Diluted) for the year ending March 31, 2021 was USD -0.25, a -821.33% change year over year.
Cybin Inc. EPS (Diluted) for the year ending March 31, 2020 was USD -0.03, a -406.47% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NYSE American: CYBN

Cybin Inc.

CEO	Mr. Douglas L. Drysdale
IPO Date	Sept. 13, 2019
Location	Canada
Headquarters	100 King Street West
Employees	50
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.

Key trends

Past 5 years